Chemours Company (CC) concluded trading on Thursday at a closing price of $11.04, with 3.86 million shares of worth about $42.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.27% during that period and on May 15, 2025 the price saw a loss of about -3.33%. Currently the company’s common shares owned by public are about 149.57M shares, out of which, 148.48M shares are available for trading.
Stock saw a price change of -1.78% in past 5 days and over the past one month there was a price change of -0.63%. Year-to-date (YTD), CC shares are showing a performance of -34.67% which decreased to -61.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.33 but also hit the highest price of $29.18 during that period. The average intraday trading volume for Chemours Company shares is 3.52 million. The stock is currently trading -6.80% below its 20-day simple moving average (SMA20), while that difference is down -11.92% for SMA50 and it goes to -36.00% lower than SMA200.
Chemours Company (NYSE: CC) currently have 149.57M outstanding shares and institutions hold larger chunk of about 92.24% of that.
The stock has a current market capitalization of $1.65B and its 3Y-monthly beta is at 1.67. PE ratio of stock for trailing 12 months is 53.64, while it has posted earnings per share of $0.21 in the same period. Its PEG reads 1.62 and has Quick Ratio of 0.83 while making debt-to-equity ratio of 7.57. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CC, volatility over the week remained 3.98% while standing at 4.63% over the month.
Stock’s fiscal year EPS is expected to rise by 32.74% while it is estimated to increase by 51.54% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on March 27, 2025 offering an Outperform rating for the stock and assigned a target price of $19 to it. Coverage by Truist stated Chemours Company (CC) stock as a Buy in their note to investors on January 28, 2025, suggesting a price target of $27 for the stock. On July 09, 2024, UBS Upgrade their recommendations, while on June 07, 2024, Mizuho Initiated their ratings for the stock with a price target of $25. Stock get an Outperform rating from BMO Capital Markets on April 09, 2024.
